Desloratadine Patent Claims No Bar To Generic Claritin, Judge Says
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough will not be able to rely on patent claims covering desloratadine to keep generic versions of its Claritin antihistamine off the OTC market before 2004 if a federal judge's ruling is upheld on appeal
You may also be interested in...
Claritin Litigation Rehearing Denial Could Affect New Drug Patents
A Washington, D.C. federal appeals court ruling not to rehear Schering-Plough's adverse desloratadine patent infringement decision en banc could hold serious implications for future new drugs and biologics, two dissenting judges argue
Claritin Litigation Rehearing Denial Could Affect New Drug Patents
A Washington, D.C. federal appeals court ruling not to rehear Schering-Plough's adverse desloratadine patent infringement decision en banc could hold serious implications for future new drugs and biologics, two dissenting judges argue
Claritin Litigation Rehearing Denial Could Affect New Drug Patents
A Washington, D.C. federal appeals court ruling not to rehear Schering-Plough's adverse desloratadine patent infringement decision en banc could hold serious implications for future new drugs and biologics, two dissenting judges argue